Nuchev Pty Ltd · ASX:NUC
Nuchev Pty — Shareholder Meeting (November 2024)
19 slides from Nuchev Pty's shareholder meeting presentation, Nov 28, 2024
Slide 1: Annual General Meeting: Chair's Address and Operational Update
ASX ANNOUNCEMENT | 28 November 2024 Annual General Meeting Chair’s Address and Operational Update Nuchev Limited (ASX: NUC) (Nuchev or the Company) is pleased to release the following Chair’s Address and Operational Update Presentation which will be delivered to Shareholders at the Company’s Annual
Slide 2: Chair's Address
ASX ANNOUNCEMENT | 28 November 2024 Chair’s Address Nuchev Ltd | AGM | 2.00pm AEDT | 28 November 2024 A YEAR OF GROWTH 2024 has been a pivotal year for Nuchev in which we delivered on our growth ambitions. We have unlocked new market opportunities, strengthened customer value through strong manufact
Slide 3: 2024 Performance
ASX ANNOUNCEMENT | 28 November 2024 2024 PERFORMANCE I am pleased to report that in FY24, we delivered branded sales revenue of $10.9 million for the year, up 45% on the prior year with an adjusted EBITDA of $5.9 million, this represented a 20% improvement due to the growth in sales, stronger margin
Slide 4: Our Future Looks Bright
ASX ANNOUNCEMENT | 28 November 2024 I would like to acknowledge and pay tribute to our outstanding executive team and fellow Directors for continuing to represent the needs of our consumers, customers, team members, shareholders, and the communities we serve. OUR FUTURE LOOKS BRIGHT At the core of o
Slide 5: 2024 Annual General Meeting
For personal use only 2024 Annual General Meeting Thursday 28 November 2024 at 2.00pm AEDT
Slide 6: Board & Management
Board & Management For personal use only Ben Dingle Nathan Cheong Jeff Martin Craig Silbery Elizabeth Smith Non-Executive Director and Chair Non-Executive Director Non-Executive Director Non-Executive Director Non-Executive Director Mick Myers Tamara Barr Eddie MacDonald Chief Executive Officer Comp
Slide 7: Our strategic ambition
ad ¢ ° one > Our strategic ambition How we work i oO In 2024, we reset our strategic ambition with a bold new vision and brand positioning refresh. We are . Ambitious We dare to dream big Why we are here What we will be known for Sedalia Tp) We're passionate Quality Dependability , We consider our —
Slide 8: Our purpose and growth strategy
Our purpose and growth strategy For personal use only 4
Slide 9: FY24 highlights
For personal use only 15% Sustained growth in Australia and New Zealand (ANZ) retail sales (grocery and pharmacy) for Oli6 Nutritionals Acquisition builds scale and diversification, unlocks access to the wellness sector with proforma Group sales of $20.6n° LV) 80% Increase in China Increase in Oli6
Slide 10: FY24 Business Highlights
FY24 Business Highlights • Acquisition of bWellness was a highlight in the year – executing our strategy to accelerate our push to breakeven, For personal use only enabling the Group to build scale, diversification and access the wellness sector with proforma Group sales of $20.6m1 • Oli6® Nutrition
Slide 11: FY24 Sales Revenue
FY24 Sales Revenue Sales Revenue1 ($ millions) Significant jump in Oli6® Nutritionals sales revenue1 For personal use only 12.0 10.9 • Group sales of Oli6® Nutritionals $10.9m up $3.4m or 10.0 45% pcp2 7.2 7.5 8.0 6.1 • China CBEC sales of Oli6® Nutritionals of $6.1m, and 6.0 3.9 3.4 uplift of $2.7m
Slide 12: FY24 Adjusted EBITDA
FY24 Adjusted EBITDA $ millions FY24 FY23 Significant growth in sales revenue1 1 Oli6 Nutritionals Sales Revenue 10.9 7.5 • Oli6® sales revenue in FY24 increased $3.4m or 45% pcp2 For personal use only Cost of sales (excluding raw material sales) (7.0) (5.0) Gross Profit 3.9 2.5 Improved gross profi
Slide 13: Net cash flows used in operations
Less cash used in operations Net cash flows used in operations Improved operating results, margins and Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 disciplined working capital management ensured For personal use only 0 the Group maintained control over cash -500 Adjusted c
Slide 14: FY24 Balance Sheet
FY24 Balance Sheet $ millions 30 Jun 2024 30 June 2023 Cash For personal use only Cash and short-term deposits 7.6 7.5 • Closing cash position in line with FY23 at $7.6m, reflecting the impact of the Trade and other receivables 2.2 0.7 June 2024 equity raise less cash used in operations during the y
Slide 15: Key Priorities in FY25
Key Priorities in FY25 1. Integration of bWellness with improved operational performance delivering sales growth, increased diversification of For personal use only sales channels, positive cash contribution and working capital benefits 2. Leveraging our strategic distribution agreement with H&S Gro
Slide 16: Q1 FY25 Update
Q1 FY25 Update • bWellness acquisition delivers scale and adds diversification into the ANZ practitioner channel, with Group revenue1 of $5.1m in Q1 FY25, up $2.7m or +116% QoQ2 and $1.5m or +41% pcp3 For personal use only • Q1 FY25 revenue from Oli6® Nutritionals in ANZ and China CBEC of $2.5m or +
Slide 17: Q1 FY25 Group Revenue Comparison
Q1 FY25 Group Revenue Comparison For personal use only 13
Slide 18: Appendix
Appendix 1 (a) Reconciliation of operating loss and Adjusted EBITDA: $ millions FY24 FY23 For personal use only Operating loss per financial statements (7.4) (8.7) Impairment of assets 0.1 0.6 Product Obsolescence & provisioning 0.3 0.6 Depreciation 0.1 0.2 Business combination costs on acquisition
Slide 19: Disclaimer
Disclaimer This presentation is provided by Nuchev Limited (ACN 163 225 090) (Nuchev) to provide summary information about Nuchev and its respective subsidiaries (together, the Group) in relation to a pro-rata non-renounceable entitlement offer of fully paid ordinary shares in Nuchev (New Shares) to